VENLAFAXINE XR 75mg Capsules Recalled Due to Dissolution Issues

Source: Health Canada · Canada

Areazine synthesizes this Health Canada recall directly from Health Canada's official public data feed. See our methodology for full source attribution and refresh cadence.

Pro-Doc Ltée. is recalling one lot of VENLAFAXINE XR extended-release capsules because the product's dissolution was found to be out of specification.

What this Health Canada recall tells you, and what most readers miss

This notice was issued by Health Canada on April 6, 2026 and geographically references Canada. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Product & Food Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.

Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.

Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, health-canada, pharmaceutical.

What Happened

Pro-Doc Ltée. has initiated a recall for a specific batch of VENLAFAXINE XR 75mg capsules. The recall was issued because the dissolution rate of the medication in the affected lot is out of specification, which may affect how the drug is released and absorbed in the body.

Which Products Are Affected

The recall involves the following product:

  • Product Name: VENLAFAXINE XR (Venlafaxine Hydrochloride)
  • Strength: 75mg
  • Dosage Form: Capsule (extended release)
  • DIN (Drug Identification Number): 02339250
  • Lot Number: 2505003230
  • Company: Pro-Doc Ltée., located at 2925 boul. Industriel, Laval, Qc, H7L 3W9.

What You Should Do

Consumers are advised to verify if their product is part of the affected lot. Before discontinuing the use of the medication, you must consult your healthcare provider, as stopping this type of medication abruptly can have health implications. For questions regarding the recall, contact Pro-Doc Ltée. directly. Any health product-related side effects or safety complaints should be reported to Health Canada.

Why This Matters

When a medication's dissolution is out of specification, it means the drug may not dissolve at the intended rate. This can lead to inconsistent levels of the medication in the patient's system, potentially reducing the drug's effectiveness or increasing the risk of side effects.

Source

Health Canada

Original source: Health Canada Official Notice ↗

All Product & Food Recalls →

Frequently Asked Questions

Common questions about this Health Canada recall.

What is this Health Canada recall about?
Pro-Doc Ltée. is recalling one lot of VENLAFAXINE XR extended-release capsules because the product's dissolution was found to be out of specification.
Which agency issued this alert?
This alert was issued by Health Canada. The original notice is available at the source link at the bottom of this article.
How severe is this alert?
This alert is classified as "high" severity. Take precautions and monitor for updates.
What area is affected?
This alert affects Canada. Check with Health Canada for the most current geographic scope.
Where can I find more Product & Food Recalls updates?
Browse the full Product & Food Recalls feed on Areazine at areazine.com/ca/recalls/ for the latest updates from Health Canada and other agencies.